<DOC>
	<DOCNO>NCT02795520</DOCNO>
	<brief_summary>The purpose Phase I study test safety tolerability investigational drug , OTS167 , Phase II study confirm potential response benefit OTS167 . OTS167 maternal embryonic leucine zipper kinase ( MELK ) inhibitor demonstrate antitumor property laboratory test . It develop anti-cancer drug . In study OTS167 administrate patient AML , ALL , advance MDSs , advance MPNs , advance CML .</brief_summary>
	<brief_title>Pharmacological Study Intravenous OTS167 Patients With Refractory Relapsed Acute Myeloid Leukemia , Acute Lymphoblastic Leukemia , Advanced Myelodysplastic Syndromes , Advanced Myeloproliferative Neoplastic Disorders , Advanced Chronic Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>1 . Diagnosis relapse refractory AML , ALL , acute biphenotypic leukemia ( assigned appropriate group treat physician pathology/cytogenetics ) , advance MDS define ≥10 % bone marrow blast , advance MPN , MDS/MPN overlap syndrome ≥10 % bone marrow blast , advance CML failure least 3 TKIs 2 . Age ≥18 year 3 . No prior antineoplastic drug therapy least 14 day , exception hydroxyurea , prior start OTS167 . Patients rapidly proliferative disease may continue receive hydroxyurea . 4 . Patients diagnosis advance CML must treat 3 prior TKIs , last therapy must discontinue 14 day prior start OTS167 . 5 . Adequate organ function define : Liver function ( total bilirubin &lt; 2mg/dL aspartate aminotransferase and/or alanine aminotransferase &lt; 3 × upper limit normal ( ULN ) &lt; 5 × ULN relate leukemic involvement ) Renal function ( creatinine &lt; 1.5 × ULN ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 7 . Negative urine pregnancy test within 1 week prior Cycle 1 Day 1 woman childbearing potential 8 . Able understand potential risk , benefit , requirement study willing provide inform consent ; inform consent form study sign patient his/her legally authorize representative require prior enrollment 1 . Diagnosis relapse refractory AML , ALL , acute biphenotypic leukemia ( assigned appropriate group treat physician pathology/cytogenetics ) , advance MDS define ≥10 % bone marrow blast , advance MPN , MDS/MPN overlap syndrome ≥10 % bone marrow blast , advance CML failure least 3 TKIs 2 . Age ≥18 year 3 . No prior antineoplastic drug therapy least 14 day , exception hydroxyurea , prior start OTS167 . Patients rapidly proliferative disease may continue receive hydroxyurea . 4 . Patients diagnosis advance CML must treat 3 prior TKIs , last therapy must discontinue 14 day prior start OTS167 . 5 . Adequate organ function define : Liver function ( total bilirubin &lt; 2mg/dL aspartate aminotransferase and/or alanine aminotransferase &lt; 3 × upper limit normal ( ULN ) &lt; 5 × ULN relate leukemic involvement ) Renal function ( creatinine &lt; 1.5 × ULN ) 6 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 7 . Negative urine pregnancy test within 1 week prior Cycle 1 Day 1 woman childbearing potential 8 . Able understand potential risk , benefit , requirement study willing provide inform consent ; inform consent form study sign patient his/her legally authorize representative require prior enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>